9月16日上午，首款国产九价HPV疫苗"馨可宁9"在郑州市郑东新区博学路社区卫生服务中心完成首针接 种，标志着该疫苗正式进入河南市场。 宫颈癌是女性最常见的恶性肿瘤之一，其主要成因是高危型人乳头瘤病毒（HPV）的持续感染。接种 HPV疫苗是预防宫颈癌最有效且经济的手段。然而，我国HPV疫苗覆盖率仍处于较低水平，价格一直被 业内认为是影响接种率的关键因素。专家指出，首款国产九价HPV疫苗的上市，将在价格方面为接种者 带来明显优势。 据了解，目前，首批疫苗已经配送至河南省部分市、县、区的疾控中心，预计9月中下旬将覆盖全省， 需要接种的女性可以及时关注周边接种门诊的相关信息。 今后可以免费接种？ 国产与进口疫苗有何不同？ 近期，有消息称HPV疫苗有望纳入免疫规划。吴小博说，将HPV疫苗纳入国家免疫规划，是政府为保障 国民健康推行的重要举措。目前国家与各省市正在积极论证和研究具体落实方案，以确保该政策的科学 性与可行性。这是一项涉及疫苗供应、资金保障与地区差异的系统工程。一旦有明确的政策与时间表， 疾控部门将及时向社会公布。在此之前，HPV疫苗仍属于自费自愿接种范畴。（记者 李晓敏） 郑东新区疾病预防控制中心免疫规划 ...

Core Viewpoint - The launch of the first domestically produced nine-valent HPV vaccine "Xinkening 9" in Zhengzhou marks a significant step in increasing HPV vaccination rates in China, particularly among women aged 9 to 45 [2][3]. Group 1: Vaccine Launch and Reception - The first day of vaccination saw nearly 200 appointments, primarily from women in their twenties and thirties, indicating strong demand for the domestic HPV vaccine [3]. - The introduction of the domestic nine-valent HPV vaccine is expected to address the low vaccination coverage in China, which was only 10.15% for the first dose in 2022 [3]. Group 2: Comparison of Domestic and Imported Vaccines - The main differences between domestic and imported nine-valent HPV vaccines lie in the manufacturers, pricing, target populations, and some production details, but both have been validated for safety and efficacy [4]. - The domestic vaccine utilizes a novel E. coli virus-like particle expression technology, which is designed to induce a high immune response [4]. Group 3: Pricing and Accessibility - The price of the domestic nine-valent HPV vaccine is set at 499 yuan per dose, which is less than half the price of imported alternatives, making it more accessible [5]. - The vaccination schedule for women aged 9 to 17 requires two doses at a total cost of approximately 1000 yuan, while women aged 18 to 45 need three doses at around 1500 yuan [5]. Group 4: Future Developments - The first batch of the vaccine is expected to be distributed to community health service centers across Henan province by mid to late September [6]. - There are discussions about including the HPV vaccine in the national immunization program, which could potentially make it available for free in the future, although it currently remains a self-paid option [7].

Core Viewpoint - The approval of the domestic nine-valent HPV vaccine "Xinkening 9" marks a significant shift in the market, breaking the long-standing monopoly of imported vaccines and enhancing China's capability to independently supply high-priced HPV vaccines [1][12]. Group 1: Vaccine Development and Innovation - The nine-valent HPV vaccine was developed by a collaboration between Xiamen University and Wantai Vaccine, utilizing a novel prokaryotic expression system based on E. coli, which is a departure from traditional eukaryotic systems [2][4]. - The research team began their HPV vaccine studies in 2002, recognizing the potential of vaccines to prevent cervical cancer, which is a leading cause of cancer among women [3][4]. - The vaccine development faced challenges, particularly regarding patent issues, as major vaccine technologies were dominated by foreign companies [4][5]. Group 2: Clinical Trials and Efficacy - The nine-valent HPV vaccine has undergone five clinical trials since 2019, involving over 11,000 healthy volunteers aged 9 to 45, demonstrating good safety profiles [7]. - Head-to-head clinical trial results published in The Lancet indicate that "Xinkening 9" has similar immune responses and safety profiles compared to imported vaccines [7]. Group 3: Production Capacity and Market Impact - The production of the nine-valent HPV vaccine is set to significantly increase, with an initial capacity of 20 million doses per year, and plans for further expansion [13][14]. - The vaccine is priced at 499 yuan per dose, approximately 40% lower than imported alternatives, which is expected to enhance accessibility for the population [15]. Group 4: Strategic Importance and Future Outlook - The launch of the domestic nine-valent HPV vaccine aligns with global health initiatives aimed at eliminating cervical cancer, reflecting China's evolving role in global health governance [15]. - The successful development of this vaccine represents a shift from imitation to original innovation in China's biopharmaceutical industry, potentially transforming the global HPV vaccine landscape [7][10].

Core Viewpoint - The launch of the domestic nine-valent HPV vaccine "Xinkening 9" by Wantai Biological Pharmacy is a significant advancement in the market, offering a cost-effective alternative to imported vaccines, priced at approximately 40% of the import cost [1][6]. Group 1: Vaccine Efficacy and Safety - "Xinkening 9" has demonstrated comparable immune response and safety to imported nine-valent HPV vaccines, as evidenced by head-to-head clinical trial results published in The Lancet Infectious Diseases [2]. - The vaccine effectively prevents persistent infections from seven high-risk HPV types associated with cervical cancer, establishing a protective barrier for women aged 18-45 [2]. Group 2: Market Impact and Accessibility - As the only approved HPV vaccine for ages 9-17 with a two-dose regimen, "Xinkening 9" is expected to significantly improve vaccination compliance and rates among young girls in China [3]. - The pricing strategy of "Xinkening 9" is anticipated to enhance the willingness of eligible women to receive the vaccine, contributing to the establishment of a national immunity barrier against cervical cancer [6]. Group 3: Research and Development Achievements - The development of "Xinkening 9" reflects over 18 years of collaborative research between Xiamen University and Wantai Biological, showcasing China's advancements in HPV vaccine technology [4]. - Wantai Biological has invested approximately 1 billion yuan in the research and development of the nine-valent HPV vaccine, highlighting the commitment to innovation in this field [5]. Group 4: Public Health Implications - The introduction of a more affordable HPV vaccine aligns with global and national strategies to accelerate the elimination of cervical cancer, with a significant portion of the target population in China yet to receive vaccination [2][6].